As Celgene Corp (CELG) Market Value Rose, Green Valley Investors LLC Decreased Holding

September 30, 2018 - By William Brooks

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.71 in Q2 2018. Its down 0.08, from 0.79 in 2018Q1. It turned negative, as 68 investors sold CELG shares while 495 reduced holdings. 98 funds opened positions while 300 raised stakes. 476.86 million shares or 7.08% less from 513.18 million shares in 2018Q1 were reported. Pennsylvania-based Janney Capital Mgmt Limited Liability has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Pdt Partners Ltd Llc reported 0.66% of its portfolio in Celgene Corporation (NASDAQ:CELG). Savings Bank Of The West, California-based fund reported 10,418 shares. Huntington Financial Bank reported 32,014 shares stake. Sumitomo Mitsui Asset Management Communication Ltd has 0.11% invested in Celgene Corporation (NASDAQ:CELG) for 89,217 shares. Secor Advsrs Limited Partnership has 17,969 shares. Hightower Advisors Ltd Co has 0.15% invested in Celgene Corporation (NASDAQ:CELG). Murphy Cap Management Inc invested in 25,433 shares or 0.29% of the stock. Profit Mngmt Ltd Liability Corp holds 9,060 shares. Hilton Cap Mgmt Ltd Llc reported 0.08% of its portfolio in Celgene Corporation (NASDAQ:CELG). Commerce Bancorporation invested 0.15% in Celgene Corporation (NASDAQ:CELG). Credit Agricole S A reported 12,355 shares or 0.07% of all its holdings. Koshinski Asset Mgmt holds 0.25% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 5,864 shares. Pictet Bank & Tru owns 40,040 shares for 1.09% of their portfolio. Ascend Ltd holds 0.37% or 98,850 shares.

Since May 8, 2018, it had 1 insider purchase, and 2 insider sales for $2.33 million activity. $1.40M worth of stock was sold by LOUGHLIN JAMES J on Monday, June 4. The insider CASEY MICHAEL D sold $1.02 million.

Green Valley Investors Llc decreased its stake in Celgene Corp (CELG) by 6.59% based on its latest 2018Q2 regulatory filing with the SEC. Green Valley Investors Llc sold 85,791 shares as the company’s stock rose 12.17% with the market. The institutional investor held 1.22M shares of the major pharmaceuticals company at the end of 2018Q2, valued at $96.58M, down from 1.30M at the end of the previous reported quarter. Green Valley Investors Llc who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $62.94 billion market cap company. The stock increased 0.27% or $0.24 during the last trading session, reaching $89.49. About 2.59M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 38.90% since September 30, 2017 and is downtrending. It has underperformed by 54.52% the S&P500.

Green Valley Investors Llc, which manages about $2.13 billion US Long portfolio, upped its stake in Unitedhealth Group Inc (NYSE:UNH) by 80,190 shares to 525,353 shares, valued at $128.89 million in 2018Q2, according to the filing.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 25. They expect $2.00 EPS, up 12.36 % or $0.22 from last year’s $1.78 per share. CELG’s profit will be $1.41 billion for 11.19 P/E if the $2.00 EPS becomes a reality. After $1.86 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 7.53 % EPS growth.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Will Revlimid’s Patent Protection Hold Up For Celgene?” on September 05, 2018, also Nasdaq.com with their article: “3 Top Biotech Stocks to Buy Right Now” published on September 23, 2018, Seekingalpha.com published: “Celgene backs away from OncoMed’s navicixizumab” on September 20, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “2 Stocks That Could Benefit Big From Geron’s Stumble” published on September 29, 2018 as well as Fool.com‘s news article titled: “Is Now a Good Time to Buy Celgene?” with publication date: September 08, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 9 analysts covering Celgene (NASDAQ:CELG), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Celgene had 13 analyst reports since April 4, 2018 according to SRatingsIntel. The company was maintained on Friday, July 13 by Morgan Stanley. RBC Capital Markets maintained Celgene Corporation (NASDAQ:CELG) on Wednesday, April 4 with “Buy” rating. As per Monday, May 7, the company rating was maintained by Morgan Stanley. RBC Capital Markets downgraded Celgene Corporation (NASDAQ:CELG) on Monday, May 7 to “Outperform” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, July 27. The firm has “Buy” rating by Oppenheimer given on Friday, May 25. Morgan Stanley maintained it with “Equal-Weight” rating and $93 target in Friday, April 13 report. The firm has “Hold” rating by Argus Research given on Wednesday, May 23. The rating was upgraded by Standpoint Research on Monday, June 18 to “Buy”. On Wednesday, May 23 the stock rating was upgraded by Bernstein to “Buy”.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: